Share this post
Natural support for gut health from a probiotic yeast
Probiotics are “live microorganisms which, when administered in adequate amounts, confer a health benefit on the host.”[1] You may be familiar with probiotic supplements that contain lactobacilli and/or bifidobacteria, which are families of beneficial bacteria.[2] However, there is also a yeast species that qualifies as a probiotic: Saccharomyces boulardii, pronounced “SAK-a roe-MYE-sees boo-LAR-dee-eye.”[3],[4] S. boulardii is related to common baker’s and brewer’s yeast (S. cerevisiae), but there are key differences that allow the former to benefit gut health.[5],[6],[7]
S. boulardii has an interesting history dating back to the last century. The yeast was discovered and named after scientist Henri Boulard who was doing research in Indochina in the 1920s. During a cholera outbreak, Boulard noticed that some people chewing the skin of lychee and mangosteen, or preparing teas from these tropical fruits, did not develop cholera symptoms.[3] He isolated a yeast strain, later named S. boulardii, which was responsible for the effects. The strains of S. boulardii used in probiotic supplementation today are closely related to Boulard’s strain.[8]
The properties and benefits of S. boulardii have been reported in more than 600 peer-reviewed articles and over 90 clinical trials.
S. boulardii achieves peak concentrations in the intestine within 3 to 4 days, and maintains a high stable level as long as the yeast is taken daily in adequate amounts.[5],[9] The properties and benefits of S. boulardii have been reported in more than 600 peer-reviewed articles and over 90 clinical trials, which are highlighted here:
- Supports a healthy microbiome: S. boulardii creates a favorable growth environment for the beneficial intestinal microbiota.[10],[11] It accelerates the recovery of the microbiota after antibiotics,[12],[13],[14] and increases the numbers of bacteria that produce butyrate,[15],[16] a short-chain fatty acid that reduces inflammation.[17]
- Protects intestinal cells from damage: S. boulardii interacts with the intestinal mucosa to preserve the integrity of the epithelial cell layer, enhance wound repair, and reduce leaky gut.[18],[19],[20],[21],[22]
- Improves digestion: S. boulardii increases the intestinal activity of digestive enzymes, including sucrase, maltase, and lactase, which may benefit people with digestive issues.[23],[24] This increase in enzyme activity may improve the absorption of carbohydrates which have been associated with irritable bowel syndrome (IBS) and diarrhea.[25]
- Releases nutrients: S. boulardii releases 1,500 different substances, including amino acids, nucleic acids, polyamines, antioxidants, flavonoids, B vitamins, minerals, and prebiotics such as beta-glucan, which enhance nutrition of the host and of the microbiota.[3],[22],[24],[26]
- Inhibits pathogens: Supplementation with S. boulardii helps protect against gut pathogens, including Clostridum difficile (C. difficile), and reduces the risk of diarrhea from many causes, as discussed below.
Anti-microbial effects of S. boulardii
International guidelines recommend the use of S. boulardii for children with gastroenteritis caused by rotavirus infection.[27],[28],[29] Supplementation with S. boulardii helps restore the normal microbiota, an effect that is correlated with a reduction in diarrhea.[30]
S. boulardii supplementation also reduces the risk of diarrhea from gastrointestinal infections, antibiotic use, and IBS.[31],[32],[33] In one study of individuals with IBS and diarrhea, supplementation with S. boulardii (200 mg three times daily) significantly improved IBS symptoms after one month.[34]
The probiotic activity of S. boulardii is especially relevant for antibiotic-associated diarrhea (AAD) and C. difficile infections.[35] Diarrhea is a common side effect of antibiotic administration,[36] and the use of S. boulardii can significantly reduce the incidence, duration and/or severity of AAD.[14],[37],[38],[39] S. boulardii reduces this risk in part by protecting and restoring levels of healthy gut microbes.[10],[37] Since S. boulardii is affected only by antifungal medications and not by antibiotics, it has a big advantage over bacterial probiotics for this indication. [40]
Since S. boulardii is affected only by antifungal medications and not by antibiotics, it has a big advantage over bacterial probiotics for this indication.
C. difficile, a pathogenic bacterium that causes colitis, is actually responsible for up to 25% of AAD cases.[41],[42] Studies show that C. difficile normally exists at very low levels in the healthy colon, but it can flourish when antibiotics destroy large numbers of protective gut microbes.[43] The destruction of indigenous bacteria that metabolize bile acids causes an accumulation of cholic acid, a primary bile acid, which triggers the growth of C. difficile in the intestine.[44],[45] Then, once C. difficile takes hold, it carries out a form of chemical warfare by inducing other gut microbes to produce indole, a substance that limits the growth of beneficial bacteria and hampers microbiota recovery.[46]
S. boulardii has its own, equally clever means of combating C. difficile.
Fortunately, S. boulardii has its own, equally clever means of combating C. difficile. It prevents the accumulation of cholic acid, which puts the brakes on C. difficile growth.[44] In this respect the action of S. boulardii is similar to that of fecal microbiota transplantation (a more extreme approach that replaces the entire microbiota with that of a healthy individual) which also may exert its effects by modulating colonic bile acid composition.[47]
By these and other mechanisms, S. boulardii also can help prevent the recurrence of C. difficile infection. In one study, when S. boulardii was taken daily for one month (1 gram per day) along with high-dose vancomycin, a significant decrease in recurrences was observed in patients, with only 16.7% having a recurrence versus 50% in those only taking the vancomycin.[14]
S. boulardii also may be helpful for individuals with Helicobacter pylori infection, which is typically treated with two different antibiotics and a proton pump inhibitor.[48],[49],[50] This drug combination is a double whammy, because both antibiotics and proton pump inhibitors increase the risk of diarrhea and C. difficile.[51] Thankfully, the administration of probiotics can reduce the side effects of H. pylori treatment, and may even increase the overall efficacy.[2] A recent clinical trial showed that S. boulardii, taken in tandem with the indicated pharmaceutical treatments for H. pylori, reduced the incidence of diarrhea from 46% in the control group to only 2% in the S. boulardii group.[50]
In laboratory studies, S. boulardii was shown to antagonize Salmonella, Escherichia coli (E. coli), Listeria, and Staphylococcus aureus, suggesting a broad range of activity against these additional gastrointestinal pathogens.[52],[53],[54],[55] S. boulardii also was shown to inhibit the growth of Candida spp., the most common cause of human fungal infections.[56],[57],[58] Researchers discovered that S. boulardii secretes capric acid, a medium-chain fatty acid that strongly inhibits C. albicans.[59]
Finally, animal and human studies suggest that supplemental S. boulardii may be useful in treatment of Giardia lamblia, a parasite that lives in contaminated water and causes the diarrheal illness known as giardiasis.[60],[61] In the United States, G. lamblia is the most common intestinal parasitic disease affecting humans.[62]
Summary
If Henri Boulard were alive today, he might be surprised to find that his 1920 discovery of a yeast strain from lychee fruit has led to one of the most successful probiotic species of all time. The multiple mechanisms of action of S. boulardii may explain its beneficial effects in a variety of gastrointestinal conditions. Collectively, the research shows that S. boulardii may be a good choice to protect and restore a healthy gut microbiota as it shields the gut against the damaging effects of antibiotics and reduces pathogen virulence as well.
Click here to see References[1] Food and Agriculture Organization of the United Nations/World Health Organization Working Group. Guidelines for the evaluation of probiotics in food [Internet]. Report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food. London (Ontario), Canada; 2002 [cited 2019 Apr 29]. Available at: https://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf
[2] Ruggiero P. Use of probiotics in the fight against Helicobacter pylori. World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):384-91.
[3] Łukaszewicz M. Saccharomyces cerevisiae var. boulardii – probiotic yeast. InProbiotics 2012 Oct 3. IntechOpen.
[4] van der Aa Kühle A, et al. In vitro screening of probiotic properties of Saccharomyces cerevisiae var. boulardii and food-borne Saccharomyces cerevisiae strains. Int J Food Microbiol. 2005 May 1;101(1):29-39.
[5] McFarland LV, Bernasconi P. Saccharomyces boulardii. A review of an innovative biotherapeutic agent. Microbial ecology in health and disease. 1993 Jan 1;6(4):157-71.
[6] Edwards-Ingram L, et al. 2007. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Appl Environ Microbiol 73:2458-67.
[7] Fietto JL, et al. Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii. Can J Microbiol. 2004 Aug;50(8):615-21.
[8] van der Aa Kühle A, Jespersen L. The taxonomic position of Saccharomyces boulardii as evaluated by sequence analysis of the D1/D2 domain of 26S rDNA, the ITS1-5.8S rDNA-ITS2 region and the mitochondrial cytochrome-c oxidase II gene. Syst Appl Microbiol. 2003 Nov;26(4):564-71.
[9] Klein SM, et al. Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res. 1993 Nov;10(11):1615-9.
[10] Moré MI, Swidsinski A. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – a review. Clin Exp Gastroenterol. 2015 Aug 14;8:237-55.
[11] Kabbani TA, et al. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes. 2017 Jan 2;8(1):17-32.
[12] Barc MC, et al. Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: influence of Saccharomyces boulardii. Anaerobe. 2008 Oct;14(4):229-33.
[13] Sniffen JC, et al. Choosing an appropriate probiotic product for your patient: an evidence-based practical guide. PLoS One. 2018 Dec 26;13(12):e0209205.
[14] Surawicz CM, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000 Oct;31(4):1012-7.
[15] Schneider SM, et al. Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J Gastroenterol. 2005 Oct 21;11(39):6165-9.
[16] Girard-Pipau F, et al. Intestinal microflora, short chain and cellular fatty acids, influence of a probiotic Saccharomyces boulardii. Microbial Ecology in Health and Disease. 2002 Jan 1;14(4):221-8.
[17] Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care. 2012 Sep;15(5):474-9.
[18] Canonici A, et al. Saccharomyces boulardii improves intestinal cell restitution through activation of the α2β1 integrin collagen receptor. PLoS One. 2011 Mar 31;6(3):e18427.
[19] Chen X, et al. Probiotic yeast inhibits VEGFR signaling and angiogenesis in intestinal inflammation. PLoS One. 2013 May 13;8(5):e64227.
[20] Kelsidis T, Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol. 2012 Mar;5(2):111-25.
[21] Terciolo C, et al. Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption. Clin Exp Gastroenterol. 2019 Feb 11;12:67-82.
[22] Stier H, Bischoff SC. Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. Clin Exp Gastroenterol. 2016 Sep 13;9:269-79.
[23] Buts JP. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res. 1986 Feb;20(2):192-6.
[24] Moré MI, Vandenplas Y. Saccharomyces boulardii CNCM I-745 improves intestinal enzyme function: a trophic effects review. Clin Med Insights Gastroenterol. 2018 Feb 9;11:1179552217752679.
[25] Puertolas MV, Fifi AC. The role of disaccharidase deficiencies in functional abdominal pain disorders – a narrative review. Nutrients. 2018 Nov 29;10(12):1835.
[26] Datta S, et al. Antioxidant properties and global metabolite screening of the probiotic yeast Saccharomyces cerevisiae var. boulardii. J Sci Food Agric. 2017 Jul;97(9):3039-49.
[27] Lo Vecchio A, et al. Comparison of recommendations in clinical practice guidelines for acute gastroenteritis in children. J Pediatr Gastroenterol Nutr. 2016 Aug;63(2):226-35.
[28] Grandy G, et al. Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children. BMC Infect Dis. 2010 Aug 25;10:253.
[29] Htwe K, et al. Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. Am J Trop Med Hyg. 2008 Feb;78(2):214-6.
[30] Dinleyici EC, et al. Time series analysis of the microbiota of children suffering from acute infectious diarrhea and their recovery after treatment. Front Microbiol. 2018 Jun 12;9:1230.
[31] McFarland LV. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis. 2007 Mar;5(2):97-105.
[32] Brun P, et al. Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS. PLoS One. 2017 Jul 21;12(7):e0181863.
[33] Shan LS, et al. Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with acute lower respiratory tract infections. Benef Microbes. 2013 Dec 1;4(4):329-34.
[34] Bafutto M, et al. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii. Arq Gastroenterol. 2013 Oct-Dec;50(4):304-9.
[35] Czerucka D, et al. Review article: yeast as probiotics — Saccharomyces boulardii. Aliment Pharmacol Ther. 2007 Sep 15;26(6):767-78.
[36] Coté GA, Buchman AL. Antibiotic-associated diarrhoea. Expert Opin Drug Saf. 2006 May;5(3):361-72.
[37] Kabbani TA, et al. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes. 2017 Jan 2;8(1):17-32.
[38] Vermeersch SJ, et al. Economic evaluation of S. boulardii CNCM I-745 for prevention of antibiotic associated diarrhoea in hospitalized patients. Acta Gastroenterol Belg. 2018 Apr-Jun;81(2):269-76.
[39] Carstensen JW, et al. Use of prophylactic Saccharomyces boulardii to prevent Clostridium difficile infection in hospitalized patients: a controlled prospective intervention study. Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1431-9.
[40] Neut C, et al. Antibiotic susceptibility of probiotic strains: is it reasonable to combine probiotics with antibiotics? Med Mal Infect. 2017 Nov;47(7):477-83.
[41] Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008 Jan 15;46 Suppl 1:S12-8.
[42] Kelly CP, et al. Clostridium difficile colitis. N Engl J Med. 1994 Jan 27;330(4):257-62.
[43] Burdet C, et al. Antibiotic-induced dysbiosis predicts mortality in an animal model of Clostridium difficile infection. Antimicrob Agents Chemother. 2018 Sep 24;62(10):e00925-18.
[44] Kelly CP, et al. Saccharomyces boulardii CNCM I-745 modulates the fecal bile acids metabolism during antimicrobial therapy in healthy volunteers. Front Microbiol. 2019 Mar 4;10:336.
[45] Allegretti JR, et al. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther. 2016 Jun;43(11):1142-53.
[46] Darkoh C, et al. Clostridium difficile modulates the gut microbiota by inducing the production of indole, an interkingdom signaling and antimicrobial molecule. mSystems. 2019 Mar 19;4(2): e00346-18.
[47] Weingarden AR, et al. Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control Clostridium difficile germination and growth. PLoS One. 2016 Jan 20;11(1):e0147210.
[48] Szajewska H, et al. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015 Jun;41(12):1237-45.
[49] Bin Z, et al. The efficacy of Saccharomyces boulardii CNCM I-745 in addition to standard Helicobacter pylori eradication treatment in children. Pediatr Gastroenterol Hepatol Nutr. 2015 Mar;18(1):17-22.
[50] Seddik H, et al. Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial. Eur J Clin Pharmacol. 2019 May;75(5):639-45.
[51] McDonald EG, et al. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med. 2015 May;175(5):784-91.
[52] Rajkowska K, et al. Probiotic activity of Saccharomyces cerevisiae var. boulardii against human pathogens. Food Technol Biotechnol. 2012;50(2):230-6.
[53] Gut AM, et al. Salmonella infection – prevention and treatment by antibiotics and probiotic yeasts: a review. Microbiology 2018;164:1327-44.
[54] Akil I, et al. Influence of oral intake of Saccharomyces boulardii on Escherichia coli in enteric flora. Pediatr Nephrol. 2006 Jun;21(6):807-10.
[55] Hatoum R, et al. Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications. Front Microbiol. 2012 Dec 19;3:421.
[56] Berg R, et al. Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. J Infect Dis. 1993 Nov;168(5):1314-8.
[57] Pierce CG, Lopez-Ribot JL. Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opin Drug Discov. 2013 Sep;8(9):1117-26.
[58] Krasowska A, et al. The antagonistic effect of Saccharomyces boulardii on Candida albicans filamentation, adhesion and biofilm formation. FEMS Yeast Res. 2009 Dec;9(8):1312-21.
[59] Murzyn A, et al. Capric acid secreted by S. boulardii inhibits C. albicans filamentous growth, adhesion and biofilm formation. PLoS One. 2010 Aug 10;5(8):e12050.
[60] Ribeiro MRS, et al. Effect of probiotic Saccharomyces boulardii in experimental giardiasis. Benef Microbes. 2018 Sep 18;9(5):789-97.
[61] Besirbellioglu BA, et al. Saccharomyces boulardii and infection due to Giardia lamblia. Scand J Infect Dis. 2006;38(6-7):479-81.
[62] Kappus KD, et al. Intestinal parasitism in the United States: update on a continuing problem. Am J Trop Med Hyg. 1994 Jun;50(6):705-13.
The information provided is for educational purposes only. Consult your physician or healthcare provider if you have specific questions before instituting any changes in your daily lifestyle including changes in diet, exercise, and supplement use.
Share this post
Marina MacDonald, MS, PhD
Related posts
Lactobacillus plantarum DR7: A Probiotic For Stress Relief
When I was a young athlete, I would get sick to my stomach before every big game, race, or match. The stress I felt always manifested in my gut. Many people experience feelings of a “nervous stomach” because our brain and our gut are so intricately intertwined. Sayings like “trust your gut”, “feel it…
It’s Not Just Antibiotics that Potentially Harm Gut Health
Which of these prescription medications are YOU taking? Most people are aware that antibiotic medications can alter the balance of good and bad bacteria in the gut. In addition to the science we have proving this, many of us have personally experienced upset bellies and changes in stool patterns upon taking an antibiotic. However,…
Are Gluten-Free Diets Just a Fad?
Understanding celiac disease, wheat allergy, non-celiac gluten sensitivity, & other gluten-related disorders It used to be quite rare to meet somebody who avoids gluten – the protein found in wheat, rye, spelt, semolina, and triticale. Nowadays, however, gluten free dieting is all the rage. In 2016, 8% of North Americans followed a wheat- or…
Fighting Fatty Liver, Part 1 of 2
How the gut, microbes, inflammation, and diet affect the liver, and what to do about it The fatty liver epidemic Sedentary lifestyles, nutrient-poor diets, chemical exposures, and an excess of sugar and refined foods are wreaking havoc on and in our bodies more than ever before. And the effects aren’t just cosmetic – beyond…
Stomach Acidity, Dietary Intake, and the Microbiome
The gut microbiome, stomach acidity, sloths, and you. In recent years we’ve seen an explosion in the research on the importance of the collection of trillions of bacteria, viruses, and fungi living in the human body, collectively known as the microbiome. We now know that a vast array of health conditions such as obesity,[1]…
Fighting Depression and Anxiety Through the Gut
Vagus nerve stimulation for mood support (Part 2 of 2) Last week’s post examined the vagus nerve (the tenth cranial nerve) and the important role it plays in connecting the body to the brain. We explored how breath, laughter, and exercise all “tickle” the nerve to send soothing, calming signals to the brain and…
Categories
- Botanicals (56)
- GI Health (53)
- Healthy Aging (121)
- Immune Support (39)
- In The News (39)
- Kids Health (21)
- Stress and Relaxation (50)
- Uncategorized (1)
- Video (9)
- Vitamins & Minerals (51)